174 related articles for article (PubMed ID: 37738546)
21. Ancestry-specific hereditary cancer panel yields: Moving toward more personalized risk assessment.
Roberts ME; Susswein LR; Janice Cheng W; Carter NJ; Carter AC; Klein RT; Hruska KS; Marshall ML
J Genet Couns; 2020 Aug; 29(4):598-606. PubMed ID: 32227564
[TBL] [Abstract][Full Text] [Related]
22. Mainstreaming germline BRCA1/2 testing in non-mucinous epithelial ovarian cancer in the North West of England.
Flaum N; Morgan RD; Burghel GJ; Bulman M; Clamp AR; Hasan J; Mitchell CL; Badea D; Moon S; Hogg M; Hadjiyiannakis D; Clancy T; Schlecht H; Woodward ER; Crosbie EJ; Edmondson RJ; Wallace AJ; Jayson GC; Lalloo FI; Harkness EF; Evans DGR
Eur J Hum Genet; 2020 Nov; 28(11):1541-1547. PubMed ID: 32651552
[TBL] [Abstract][Full Text] [Related]
23. Comprehensive epithelial tubo-ovarian cancer risk prediction model incorporating genetic and epidemiological risk factors.
Lee A; Yang X; Tyrer J; Gentry-Maharaj A; Ryan A; Mavaddat N; Cunningham AP; Carver T; Archer S; Leslie G; Kalsi J; Gaba F; Manchanda R; Gayther S; Ramus SJ; Walter FM; Tischkowitz M; Jacobs I; Menon U; Easton DF; Pharoah P; Antoniou AC
J Med Genet; 2022 Jul; 59(7):632-643. PubMed ID: 34844974
[TBL] [Abstract][Full Text] [Related]
24. Germline Pathogenic Variant Prevalence Among Latin American and US Hispanic Individuals Undergoing Testing for Hereditary Breast and Ovarian Cancer: A Cross-Sectional Study.
Ossa Gomez CA; Achatz MI; Hurtado M; Sanabria-Salas MC; Sullcahuaman Y; Chávarri-Guerra Y; Dutil J; Nielsen SM; Esplin ED; Michalski ST; Bristow SL; Hatchell KE; Nussbaum RL; Pineda-Alvarez DE; Ashton-Prolla P
JCO Glob Oncol; 2022 Jul; 8():e2200104. PubMed ID: 35867948
[TBL] [Abstract][Full Text] [Related]
25. Frequency of germline BRCA1/2 mutations and association with clinicopathological characteristics in Turkish women with epithelial ovarian cancer.
Sunar V; Korkmaz V; Topcu V; Cavdarli B; Arik Z; Ozdal B; Ustun YE
Asia Pac J Clin Oncol; 2022 Feb; 18(1):84-92. PubMed ID: 33629534
[TBL] [Abstract][Full Text] [Related]
26.
Lanjouw L; Mourits MJE; Bart J; Ter Elst A; Berger LPV; van der Hout AH; Alam N; de Bock GH
Int J Gynecol Cancer; 2023 Aug; 33(8):1260-1269. PubMed ID: 37137525
[TBL] [Abstract][Full Text] [Related]
27.
Piedimonte S; Power J; Foulkes WD; Weber E; Palma L; Schiavi A; Ambrosio E; Konci R; Gilbert L; Jardon K; Baret L; Zeng X
Int J Gynecol Cancer; 2020 Nov; 30(11):1757-1761. PubMed ID: 32759180
[TBL] [Abstract][Full Text] [Related]
28. BRCA1, BRCA2, and TP53 germline and somatic variants and clinicopathological characteristics of Brazilian patients with epithelial ovarian cancer.
Richau CS; Scherer NM; Matta BP; de Armas EM; de Barros Moreira FC; Bergmann A; Pereira Chaves CB; Boroni M; Dos Santos ACE; Moreira MAM
Cancer Med; 2024 Feb; 13(3):e6729. PubMed ID: 38308422
[TBL] [Abstract][Full Text] [Related]
29. Racial and ethnic variation in multigene panel testing in a cohort of BRCA1/2-negative individuals who had genetic testing in a large urban comprehensive cancer center.
Tatineni S; Tarockoff M; Abdallah N; Purrington KS; Assad H; Reagle R; Petrucelli N; Simon MS
Cancer Med; 2022 Mar; 11(6):1465-1473. PubMed ID: 35040284
[TBL] [Abstract][Full Text] [Related]
30. Facilitated referral pathway for genetic testing at the time of ovarian cancer diagnosis: uptake of genetic counseling and testing and impact on patient-reported stress, anxiety and depression.
Frey MK; Lee SS; Gerber D; Schwartz ZP; Martineau J; Lutz K; Reese E; Dalton E; Olsen A; Girdler J; Pothuri B; Boyd L; Curtin JP; Levine DA; Blank SV
Gynecol Oncol; 2020 Apr; 157(1):280-286. PubMed ID: 32057464
[TBL] [Abstract][Full Text] [Related]
31. Prevalence of Pathogenic Germline
Abe A; Imoto I; Tange S; Nishimura M; Iwasa T
Genes (Basel); 2022 Jun; 13(6):. PubMed ID: 35741847
[TBL] [Abstract][Full Text] [Related]
32. Clinical Germline Testing Results of Men With Prostate Cancer: Patient-Level Factors and Implications of NCCN Guideline Expansion.
Greenberg SE; Hunt TC; Ambrose JP; Lowrance WT; Dechet CB; O'Neil BB; Tward JD
JCO Precis Oncol; 2021; 5():. PubMed ID: 34250421
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women.
Grant DJ; Manichaikul A; Alberg AJ; Bandera EV; Barnholtz-Sloan J; Bondy M; Cote ML; Funkhouser E; Moorman PG; Peres LC; Peters ES; Schwartz AG; Terry PD; Wang XQ; Keku TO; Hoyo C; Berchuck A; Sandler DP; Taylor JA; O'Brien KM; Velez Edwards DR; Edwards TL; Beeghly-Fadiel A; Wentzensen N; Pearce CL; Wu AH; Whittemore AS; McGuire V; Sieh W; Rothstein JH; Modugno F; Ness R; Moysich K; Rossing MA; Doherty JA; Sellers TA; Permuth-Way JB; Monteiro AN; Levine DA; Setiawan VW; Haiman CA; LeMarchand L; Wilkens LR; Karlan BY; Menon U; Ramus S; Gayther S; Gentry-Maharaj A; Terry KL; Cramer DW; Goode EL; Larson MC; Kaufmann SH; Cannioto R; Odunsi K; Etter JL; Huang RY; Bernardini MQ; Tone AA; May T; Goodman MT; Thompson PJ; Carney ME; Tworoger SS; Poole EM; Lambrechts D; Vergote I; Vanderstichele A; Van Nieuwenhuysen E; Anton-Culver H; Ziogas A; Brenton JD; Bjorge L; Salvensen HB; Kiemeney LA; Massuger LFAG; Pejovic T; Bruegl A; Moffitt M; Cook L; Le ND; Brooks-Wilson A; Kelemen LE; Pharoah PDP; Song H; Campbell I; Eccles D; DeFazio A; Kennedy CJ; Schildkraut JM
Cancer Med; 2019 May; 8(5):2503-2513. PubMed ID: 31001917
[TBL] [Abstract][Full Text] [Related]
34. Prevalence, spectrum, and founder effect of BRCA1 and BRCA2 mutations in epithelial ovarian cancer from the Middle East.
Siraj AK; Bu R; Iqbal K; Siraj N; Al-Haqawi W; Al-Badawi IA; Parvathareddy SK; Masoodi T; Tulbah A; Al-Dayel F; Al-Kuraya KS
Hum Mutat; 2019 Jun; 40(6):729-733. PubMed ID: 30825404
[TBL] [Abstract][Full Text] [Related]
35. Germline and somatic mutations of multi-gene panel in Chinese patients with epithelial ovarian cancer: a prospective cohort study.
Li W; Shao D; Li L; Wu M; Ma S; Tan X; Zhong S; Guo F; Wang Z; Ye M
J Ovarian Res; 2019 Aug; 12(1):80. PubMed ID: 31472684
[TBL] [Abstract][Full Text] [Related]
36. Mainstream germline genetic testing for patients with epithelial ovarian cancer leads to higher testing rates and a reduction in genetics-related healthcare costs from a healthcare payer perspective.
Bokkers K; Frederix GWJ; Velthuizen ME; van der Aa M; Gerestein CG; van Dorst EBL; Lange JG; Louwers JA; Koole W; Zweemer RP; Ausems MGEM
Gynecol Oncol; 2022 Oct; 167(1):115-122. PubMed ID: 36031452
[TBL] [Abstract][Full Text] [Related]
37. Genomic ancestry in kidney cancer: Correlations with clinical and molecular features.
Kotecha RR; Knezevic A; Arora K; Bandlamudi C; Kuo F; Carlo MI; Fitzgerald KN; Feldman DR; Shah NJ; Reznik E; Hakimi AA; Carrot-Zhang J; Mandelker D; Berger M; Lee CH; Motzer RJ; Voss MH
Cancer; 2024 Mar; 130(5):692-701. PubMed ID: 37864521
[TBL] [Abstract][Full Text] [Related]
38. Young Israeli women with epithelial ovarian cancer: prevalence of BRCA mutations and clinical correlates.
Helpman L; Zidan O; Friedman E; Kalfon S; Perri T; Ben-Baruch G; Korach J
J Gynecol Oncol; 2017 Sep; 28(5):e61. PubMed ID: 28657222
[TBL] [Abstract][Full Text] [Related]
39. BRCA1/2 in non-mucinous epithelial ovarian cancer: tumour with or without germline testing?
Morgan RD; Burghel GJ; Flaum N; Bulman M; Smith P; Clamp AR; Hasan J; Mitchell CL; Salih Z; Woodward ER; Lalloo F; Crosbie EJ; Edmondson RJ; Wallace AJ; Jayson GC; Evans DGR
Br J Cancer; 2022 Jul; 127(1):163-167. PubMed ID: 35260807
[TBL] [Abstract][Full Text] [Related]
40. Increasing genetic counseling referral rates through bundled interventions after ovarian cancer diagnosis.
Swanson CL; Kumar A; Maharaj JM; Kemppainen JL; Thomas BC; Weinhold MR; Slaby KM; Mara KC; Wick MJ; Bakkum-Gamez JN
Gynecol Oncol; 2018 Apr; 149(1):121-126. PubMed ID: 29402500
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
